Cantor Fitzgerald Reaffirms “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a report issued on Wednesday,Benzinga reports. They currently have a $2.00 price objective on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 29.45% from the stock’s previous close.

LUCD has been the subject of several other reports. Ascendiant Capital Markets reduced their price objective on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a research note on Monday, December 9th. Needham & Company LLC increased their target price on shares of Lucid Diagnostics from $2.50 to $3.00 and gave the company a “buy” rating in a research report on Monday. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Lucid Diagnostics has a consensus rating of “Buy” and a consensus price target of $3.75.

Lucid Diagnostics Stock Down 0.3 %

Shares of NASDAQ LUCD traded down $0.01 during midday trading on Wednesday, reaching $1.55. 238,982 shares of the stock were exchanged, compared to its average volume of 634,399. The firm has a market cap of $91.68 million, a price-to-earnings ratio of -1.36 and a beta of 1.34. The firm has a 50-day simple moving average of $1.23 and a two-hundred day simple moving average of $0.99. Lucid Diagnostics has a twelve month low of $0.63 and a twelve month high of $1.63.

Institutional Trading of Lucid Diagnostics

Several large investors have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. acquired a new position in shares of Lucid Diagnostics during the 4th quarter valued at about $67,000. Citadel Advisors LLC acquired a new position in Lucid Diagnostics in the 4th quarter valued at about $98,000. Lido Advisors LLC grew its stake in shares of Lucid Diagnostics by 40.0% in the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock valued at $115,000 after buying an additional 40,000 shares during the period. Geode Capital Management LLC increased its holdings in shares of Lucid Diagnostics by 30.9% during the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock worth $229,000 after buying an additional 65,964 shares during the last quarter. Finally, LPL Financial LLC raised its position in shares of Lucid Diagnostics by 29.1% during the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock valued at $44,000 after buying an additional 12,035 shares during the period. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.